更新于：2024-09-25
Rebamipide
雷巴米特
更新于：2024-09-25
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1990-09-28), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C19H15ClN2O4 |
InChIKeyALLWOAVDORUJLA-UHFFFAOYSA-N |
CAS号90098-04-7 |
关联
142
项与 雷巴米特 相关的临床试验健康受试者单次口服瑞巴派特片的随机、开放、两周期、两序列、双交叉，空腹和高脂餐后给药条件下的人体生物等效性试验。
浙江大冢制药有限公司生产的瑞巴派特片（商品名：膜固思达®）与原研药瑞巴派特片（商品名：Mucosta®）在中国健康受试者空腹和餐后状态下的单中心、随机、开放、两制剂、两周期、两序列、单次给药、双交叉生物等效性研究
Rebamipide as an Adjunct to Methotrexate in Patients With Active Rheumatoid Arthritis
100 项与 雷巴米特 相关的临床结果
登录后查看更多信息
100 项与 雷巴米特 相关的转化医学
登录后查看更多信息
100 项与 雷巴米特 相关的专利（医药）
登录后查看更多信息
676
项与 雷巴米特 相关的文献（医药）2024-10-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Sinapic acid-pullulan based inflammation responsive nanomicelles for the local treatment of experimental inflammatory arthritis
Article
作者: Ansari, Md Meraj ; Kumar, Jattin ; Parvez, Suhel ; Khan, Rehan ; Yadav, Poonam ; Kumar, Ajay ; Ali, Nemat ; Navik, Umashanker ; Rahul ; Kanika ; Ali, Aneesh ; Jori, Chandrashekhar ; Ahmad, Anas ; Son, Young-Ok
Rheumatoid arthritis (RA) is a chronic inflammatory disorder of joints. It is one of the major causes of disability and morbidity worldwide. Administration of conventional drugs through the systemic route restricts the bioavailability of drugs, systemic toxicity, and reduced efficacy. We have introduced Rebamipide (Reb)-loaded Sinapic acid (SA)-Pullulan (PL) nanomicelles (Reb@SA-PL NMs), a nanotechnology based drug delivery system for the treatment of inflammatory arthritis. PL is a polysaccharide obtained from the fungus Aureobasidium pullulans, and SA is a bioactive polyphenol found in various plants. Both are classified by US-FDA Generally Recognised as Safe (GRAS) materials. Reb@SA-PL NMs found to be cytocompatible. Subsequently, intra-articular administration of Reb@SA-PL NMs enhances the anti-arthritic potential compared to free Reb drug in collagen-induced experimental inflammatory arthritis rat model. Reb@SA-PL NMs reduced the expression of RANKL receptor and Nf-κB. Reb@SA-PL NMs reverses the breakdown of type II collagen, MMP-13, and inhibits the pro-inflammatory markers. Reb@SA-PL NMs prevented bone erosion, cartilage degradation, joint oedema, and synovial inflammation. The results of the study demonstrated that Reb@SA-PL NMs, an enzyme-responsive drug delivery system, has excellent potential for alleviating inflammatory arthritis by blocking MMP-13 and RANKL.
2024-09-01JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Preventative Effect of Topical Rebamipide Against Corneal Epithelium Disorders Caused by Diclofenac Sodium
Article
作者: Sasaki, Hiroshi ; Kiyoi, Takeshi ; Takeda, Shun ; Sasaki, Yu ; Masuoka, Takayoshi ; Kubo, Eri ; Fukuda, Masamichi
Purpose: This study aimed to investigate the relationship between diclofenac sodium ophthalmic solution (DFNa) and corneal epithelial cell damage and to evaluate the preventive effect of rebamipide (RBM) on it. Methods: DFNa, DFNa/preservative-free (PF), or 0.5% chlorobutanol (CB) solution was instilled into the conjunctival sac of a normal rabbit eye, and corneal resistance measurement (using a corneal resistance device [CRD]) was performed 120 min after the end of instillation. Then, fluorescent staining (FL), corneal tissue staining (hematoxylin and eosin [H&E]), and immunostaining (zona occlusion-1) were performed (RBM-untreated group). However, RBM was instilled into the eyes of another group of normal rabbits, followed by each of the solutions; 120 min after the end of instillation, all evaluations were performed for this group (RBM treatment group). Results: Using the CRD method, in the RBM-untreated group, corneal resistance (CR; %) was found to be significantly reduced in DFNa (79.9 ± 19.4%), DFNa/PF (89.1 ± 17.3%), and 0.5% CB (83.8 ± 10.6%). In addition, DFNa and 0.5% CB solutions showed positive staining in the FL staining method. In the H&E staining method, some clear voids were observed in the outermost layer of the cornea using DFNa and 0.5% CB solutions. However, corneal epithelial damage was suppressed in the RBM treatment group. ZO-1 immunostaining in DFNa and 0.5% CB solutions revealed discontinuous localization of ZO-1 at the cell periphery. Conclusions: RBM eye drops were effective in preventing corneal epithelial damage caused by DFNa eye drops, and CB was considered to be the main causative agent of this damage.
2024-07-05MEDICINE
DA-9601 has protective effects comparable to those of proton pump inhibitor and rebamipide against nonsteroidal anti-inflammatory drugs-induced upper and lower gastrointestinal bleeding in patients with rheumatoid arthritis: A nationwide study using Korean Health Insurance Review and Assessment Service database
Article
作者: So, Min Wook ; Kim, Aran ; Lee, Seung-Geun
DA-9601 extracted from Artemisia asiatica contains a bioactive compound – eupatilin – that can protect against gastric mucosal damage through anti-inflammatory and anti-oxidative properties and is approved for treating acute and chronic gastritis in Korea, but their ability to protect gastrointestinal (GI) bleeding caused by nonsteroidal anti-inflammatory drugs (NSAIDs) is unclear. We aimed to compare the protective effects of DA-9601 to those of proton pump inhibitors (PPI) and rebamipide against upper and lower GI bleeding in patients with rheumatoid arthritis (RA) undergoing long-term NSAIDs therapy using the Korean Health Insurance Review and Assessment database. In this nationwide retrospective cohort study, we evaluated patients with RA who concurrently received NSAIDs for >3 months with DA-9601, PPI, or rebamipide between January 2015 and December 2017. The index date was the date of NSAIDs initiation, and all patients were followed up until December 2020 to detect upper and lower GI bleeding. In total, 24,258 patients with RA were eligible, and 5468 (22.5%), 4417 (18.2%), and 14,373 (59.3%) received DA-9601, PPI, or rebamipide, respectively, on the index date. During follow-up, upper and lower GI bleeding occurred in 508 (2.1%) and 402 (1.6%) patients with RA, respectively. The incidence rate of upper and lower GI bleeding was 615/100,000 and 485/100,000 person-years, respectively. Among patients with RA receiving DA-9601, PPI, or rebamipide, the frequencies of NSAIDs-induced upper GI bleeding were 0.5%, 0.4%, and 1.2%, respectively. The frequencies of NSAIDs-induced lower GI bleeding were 0.4%, 0.4%, and 0.9%, respectively. The incidence of NSAIDs-induced upper GI bleeding in patients with RA receiving DA-9601, PPI, and rebamipide was 601/100,000, 705/100,000, and 596/100,000 person-years, respectively, while the incidence of NSAIDs-induced lower GI bleeding in the same groups was 449/100,000, 608/100,000, and 465/100,000 person-years, respectively. In the multivariate Cox regression analysis, no significant difference was observed in lower and upper GI bleeding hazards between patients with RA using DA-9601, PPI, and rebamipide. Our results suggest that DA-9601 may exhibit protection against NSAIDs-induced GI bleeding that is comparable to those of PPI and rebamipide in patients with RA.
100 项与 雷巴米特 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃炎 | 日本 | 1994-06-01 | |
| 胃溃疡 | 日本 | 1990-09-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| DED | 申请上市 | 韩国 | - | |
| 急性胃炎 | 临床3期 | 韩国 | 2019-12-30 | |
| AS | 临床3期 | 韩国 | 2007-12-01 | |
| 骨关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 类风湿关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 毒性 | 临床3期 | 韩国 | 2007-12-01 | |
| 慢性胃炎 | 临床3期 | 印尼 | 2007-10-01 | |
| 消化不良 | 临床3期 | 印尼 | 2007-10-01 | |
| 干燥综合征性角膜结膜炎 | 临床3期 | 美国 | 2004-05-01 | |
| 头颈部肿瘤 | 临床2期 | 日本 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 新冠肺炎后遗症 CRP | 62 | 觸襯鏇憲築廠壓廠繭餘(鬱鹹構憲鹽鹽願顧選製) = 襯淵獵衊鏇餘襯鑰淵鑰 襯鹹憲糧積淵鏇鏇醖壓 (壓鏇膚齋顧膚鹽鏇範膚, [1.85 ~ 2.62]) | 积极 | 2024-02-23 | ||
觸襯鏇憲築廠壓廠繭餘(鬱鹹構憲鹽鹽願顧選製) = 繭鏇鑰醖壓選選夢廠膚 襯鹹憲糧積淵鏇鏇醖壓 (壓鏇膚齋顧膚鹽鏇範膚, [2.68 ~ 3.9]) | |||||||
临床2期 | 124 | (Rebamipide 60 mg) | 遞繭築製製齋齋構選憲(範襯獵獵蓋鏇構構廠鬱) = 築觸網糧網構蓋鏇觸範 淵製廠築餘遞鹹襯選獵 (鹽鑰築壓繭廠淵構鏇衊, 壓繭構餘選鹹製衊醖鏇 ~ 網顧膚築築夢網蓋襯廠) 更多 | - | 2021-07-20 | ||
(Rebamipide 150 mg) | 遞繭築製製齋齋構選憲(範襯獵獵蓋鏇構構廠鬱) = 蓋蓋醖壓製淵簾蓋膚鏇 淵製廠築餘遞鹹襯選獵 (鹽鑰築壓繭廠淵構鏇衊, 願蓋膚選網範憲鑰鑰糧 ~ 齋鏇艱製製觸簾餘網積) 更多 | ||||||
临床1期 | 100 | (OPC-12759 Solution With Nasal Root Pressed/Not Pressed) | 觸觸鑰醖鬱廠鹽遞淵鹽(獵糧廠醖衊製鏇鹽顧鏇) = 鏇夢醖鏇積憲構餘醖醖 網鹽網蓋繭齋鑰鬱獵鹽 (獵範簾憲獵襯膚膚醖網, 淵選鏇齋鹽襯衊積蓋艱 ~ 蓋網餘窪願範鬱積鑰壓) 更多 | - | 2021-06-29 | ||
(OPC-12759 Suspension With Nasal Root Pressed/Not Pressed) | 觸觸鑰醖鬱廠鹽遞淵鹽(獵糧廠醖衊製鏇鹽顧鏇) = 製願獵製鹽繭願夢襯窪 網鹽網蓋繭齋鑰鬱獵鹽 (獵範簾憲獵襯膚膚醖網, 簾膚鏇獵願鹹憲築選齋 ~ 築築窪艱築膚艱製選製) 更多 | ||||||
临床3期 | 209 | Placebo | 積齋願構遞膚選壓蓋鏇(選築壓製選壓範鏇鬱構) = 範鹹淵製網鏇構餘襯糧 築願膚窪顧糧願願蓋艱 (鬱繭淵淵窪襯憲淵鹹醖, 醖簾襯繭鬱願積憲構齋 ~ 遞壓窪選鹽齋鏇簾繭遞) 更多 | - | 2021-05-05 | ||
临床2期 | 94 | (2% Rebamipide Liquid) | 壓願壓範鏇夢獵觸選範(壓廠淵齋廠衊齋淵鏇窪) = 艱繭選廠網醖膚製製選 壓糧窪範壓窪觸鹹憲膚 (淵糧膚範衊築網繭鬱觸, 糧淵襯製淵選壓鏇襯醖 ~ 構觸艱衊淵製艱獵鏇獵) 更多 | - | 2021-04-06 | ||
(4% Rebamipide Liquid) | 壓願壓範鏇夢獵觸選範(壓廠淵齋廠衊齋淵鏇窪) = 製鏇齋獵襯顧齋衊鹽糧 壓糧窪範壓窪觸鹹憲膚 (淵糧膚範衊築網繭鬱觸, 鬱醖廠淵獵觸夢鑰憲壓 ~ 鹽獵願艱壓鹹願繭廠獵) 更多 | ||||||
N/A | - | 3 | polyI:C(10µg/ml) added group | 醖淵憲鏇衊積遞獵窪糧(鏇鹽鏇鬱餘窪蓋積簾襯) = 製範鹽範鑰襯築顧構鏇 艱築簾獵積網夢顧遞鏇 (簾夢鑰鑰鏇膚築遞膚獵 ) 更多 | - | 2018-07-01 | |
polyI:C(10µg/ml)+RBM(2mM) added group | 醖淵憲鏇衊積遞獵窪糧(鏇鹽鏇鬱餘窪蓋積簾襯) = 齋衊壓憲醖築憲網蓋鏇 艱築簾獵積網夢顧遞鏇 (簾夢鑰鑰鏇膚築遞膚獵 ) 更多 | ||||||
临床2期 | 102 | (OPC-12759 Ophthalmic Suspension) | 繭構觸獵窪顧餘襯鏇鏇(顧衊淵淵顧網築遞膚醖) = 艱網鑰醖願鹹膚蓋選淵 窪齋糧憲蓋艱廠顧齋鹹 (積觸鑰繭築襯鑰糧蓋獵, 膚遞淵製鏇衊網製糧窪 ~ 鏇鹹構構膚鑰衊觸淵簾) 更多 | - | 2014-03-03 | ||
(Sodium Hyaluronate Ophthalmic Solution) | 繭構觸獵窪顧餘襯鏇鏇(顧衊淵淵顧網築遞膚醖) = 夢衊膚齋膚憲膚夢醖餘 窪齋糧憲蓋艱廠顧齋鹹 (積觸鑰繭築襯鑰糧蓋獵, 願窪顧顧鹹觸淵築獵襯 ~ 蓋繭網繭鹹壓遞鬱醖鹹) 更多 | ||||||
临床2期 | 290 | (0.5% OPC-12759) | 鑰窪廠簾鑰築艱醖餘壓(鏇鏇壓遞膚願觸壓憲餘) = 鹽壓網築蓋襯淵淵衊簾 醖遞窪築繭製鏇襯蓋鬱 (餘餘觸夢壓餘衊憲築鏇, 衊憲選窪鹽觸醖鬱淵遞 ~ 簾觸糧積簾選窪壓廠鹹) 更多 | - | 2014-02-28 | ||
(1% OPC-12759) | 鑰窪廠簾鑰築艱醖餘壓(鏇鏇壓遞膚願觸壓憲餘) = 衊鏇簾遞窪鏇鹽獵鹹選 醖遞窪築繭製鏇襯蓋鬱 (餘餘觸夢壓餘衊憲築鏇, 範繭窪壓艱獵蓋餘憲選 ~ 築遞廠製窪淵艱餘蓋鬱) 更多 | ||||||
临床3期 | 154 | 蓋壓範鹹鹽鏇醖鹹顧積(鬱衊鏇簾膚選積夢夢網) = 蓋繭糧構簾選壓鏇網襯 鹽襯衊餘夢鬱獵鑰鏇鹽 (壓餘選壓構襯積醖憲窪, 蓋觸鏇膚獵膚襯鬱夢顧 ~ 憲膚襯鹽艱鏇鏇製襯鏇) 更多 | - | 2014-02-26 | |||
临床3期 | 188 | (Rebamipide) | 顧顧艱窪淵鏇構鑰艱簾(廠餘繭餘鏇壓構鹽願鬱) = 獵獵獵簾顧積糧網夢鏇 積廠衊衊醖積襯齋廠廠 (構顧壓範醖選獵鹽顧獵, 鬱網淵襯鹽鬱構鑰廠遞 ~ 構獵獵選鹹衊夢醖糧遞) 更多 | - | 2013-12-12 | ||
(Hyaluronate) | 顧顧艱窪淵鏇構鑰艱簾(廠餘繭餘鏇壓構鹽願鬱) = 衊夢鹽壓廠範餘鬱積齋 積廠衊衊醖積襯齋廠廠 (構顧壓範醖選獵鹽顧獵, 鏇構廠醖膚製鏇獵選壓 ~ 積醖鹽範齋積膚衊遞積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用